Skip to main content
TipRanks
Go Ultimate75% OFF

Cue Biopharma (CUE) AI Stock Analysis

670 Followers
CUE

Cue Biopharma

(NASDAQ:CUE)

Select Model
Rating:45Neutral
Price Target:$15.50â–¼(-3.85% Downside)
Action:reiterated
Date:10/14/26

The score is held down primarily by weak financial performance (large losses, heavy cash burn, and equity erosion) and bearish technicals (price below key moving averages with negative MACD). Positive corporate events—especially encouraging Phase 2 data—provide a meaningful offset, while valuation remains difficult to support due to negative earnings and no dividend.

Positive Factors
Phase 2 Clinical ValidationPositive Phase 2 results strengthen confidence in CUE-221’s clinical profile, with dose-responsive efficacy, durability after treatment ended, and no treatment-related serious adverse events reported. Advancement toward a registration-enabling study could expand the company’s strategic and commercial opportunity.
Negative Factors
Heavy Cash BurnPersistent cash outflows of roughly $50 million on both operating and free cash flow measures create an ongoing need to fund operations externally. This dependence can constrain development plans, reduce financial flexibility, and increase the importance of securing capital on acceptable terms.

Cue Biopharma (CUE) vs. SPDR S&P 500 ETF (SPY)

-100%-50%0%50%100%150%CUE-7.36%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$117.10M
Dividend Yield
―
Average Volume (3M)
255.40K
Price to Earnings (P/E)
-0.6
Beta (1Y)
3.14
Revenue Growth
354.37%
EPS Growth
-63.33%
Country
US
Employees
29
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Cue Biopharma Business Overview & Revenue Model

Company Description

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various ca...

How the Company Makes Money

Cue Biopharma has historically generated little to no recurring product revenue because it is a clinical-stage company without approved commercial therapies. As a result, its cash inflows have primarily come from (1) collaboration and partnership arr...

Cue Biopharma Earnings Call Summary

Earnings Call Date:Aug 19, 2024(Q2-2024)|% Change Since:-29.30%|Next Earnings Date:May 09, 2024
Earnings Call SentimentNeutral

The call presented several positive developments in clinical trials and strategic financial management, but also noted delays in trial launches and competitive market challenges.

Positive Updates

CUE-101 and Pembrolizumab Combination Shows Promising Results
CUE-101 in combination with Pembrolizumab shows an objective response rate (ORR) of 46% in patients with CPS ≥ 1, compared to the historical ORR of 19% with Pembrolizumab alone. The 12-month overall survival (OS) is 90% with a median OS of 21.8 months.

Negative Updates

Delays in Capital-Intensive Trials
Measures to delay the launch of capital-intensive trials were implemented, affecting the pace of certain developments.

Company Guidance

During Cue Biopharma's Q2 2024 earnings call, the executives provided guidance on several metrics and strategic priorities. They highlighted their focus on reducing capital requirements by achieving a cash burn reduction from $40 million to $30 million annually, extending their runway to mid-2025. The company is advancing its CUE-101 and CUE-102 oncology programs, with CUE-101 showing an objective response rate of 46% and a notable 12-month overall survival rate of 90% in a combination trial with pembrolizumab. Cue-401, in collaboration with ONO Pharmaceuticals, targets autoimmune diseases, with lead candidate selection anticipated in Q1 2025. Additionally, CUE-501 is being positioned for strategic partnering, aimed at addressing B-cell-mediated autoimmune diseases. The company's approach includes leveraging strategic partnerships to optimize resource allocation and bolster cash flow through milestone payments and potential co-development agreements.

Cue Biopharma Financial Statement Overview

Summary

Financials are the primary constraint: income statement and cash flow quality are weak (large and worsening operating/net losses and heavy cash burn), while the balance sheet shows meaningful equity erosion that increases financing/dilution risk despite modest nominal debt. The main offset is improving revenue momentum and stronger gross profitability at the core business level.

Income Statement

22Negative

Balance Sheet

34Negative

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Mar 2024Dec 2022Dec 2021
Income Statement
Total Revenue37.65M27.47M9.29M5.49M1.25M14.94M
Gross Profit37.54M27.47M9.29M-32.61M1.25M16.72M
EBITDA-95.74M-24.79M-37.53M-46.05M-50.49M-45.44M
Net Income-164.11M-26.60M-40.67M-50.73M-53.01M-44.16M
Balance Sheet
Total Assets30.71M42.21M32.19M61.53M91.28M83.40M
Cash, Cash Equivalents and Short-Term Investments17.39M27.14M22.46M48.51M76.29M64.37M
Total Debt8.81M4.20M8.88M14.70M19.32M12.02M
Total Liabilities28.40M15.78M14.69M24.45M25.60M17.91M
Stockholders Equity2.31M26.43M17.50M37.09M65.68M65.49M
Cash Flow
Free Cash Flow-50.17M-21.86M-36.40M-39.96M-41.98M-39.75M
Operating Cash Flow-50.05M-21.69M-36.33M-39.96M-41.81M-38.84M
Investing Cash Flow131.00K75.00K32.00K25.00M-24.61M9.11M
Financing Cash Flow39.82M26.29M10.24M11.86M53.66M19.23M

Cue Biopharma Technical Analysis

Technical Analysis SentimentNegative
Last Price16.12

Price Trends

50DMA23.94Negative
100DMA26.58Negative
200DMA21.57Negative

Market Momentum

MACD-1.45Negative
RSI37.24Neutral
STOCH26.60Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUE, the sentiment is Negative. The current price of 16.12 is below the 20-day moving average (MA) of 18.90, below the 50-day MA of 23.94, and below the 200-day MA of 21.57, indicating a bearish trend. The MACD of -1.45 indicates Negative momentum. The RSI at 37.24 is Neutral, neither overbought nor oversold. The STOCH value of 26.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CUE.

Cue Biopharma Risk Analysis

Cue Biopharma disclosed 65 risk factors in its most recent earnings report. Cue Biopharma reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.We may derive results and data for CUE-221 from clinical trials conducted by Ascendant in China. Our access to the clinical results and data, or our access to clinical trial support services or clinical supply, may be limited and there is no assurance that the clinical data from any such trials will be accepted or considered by the FDA or other comparable regulatory authorities.Q2, 2026
2.If we fail to comply with our obligations in the agreements under which we license development or commercialization rights to products or technology from third parties, we could lose license rights that are important to our business.Q1, 2026
3.We may derive results and data for CUE-221 from clinical trials conducted by Ascendant in China. Our access to the clinical results and data, or our access to clinical trial support services or clinical supply, may be limited and there is no assurance that the clinical data from any such trials will be accepted or considered by the FDA or other comparable regulatory authorities.Q1, 2026

Cue Biopharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CUE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ACRVACRV52Neutral$62.14M-0.77-70.14%――16.04%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CUECUE45Neutral$117.10M-0.60-1032.19%―354.37%-63.33%
MAIAMAIA44Neutral$61.75M-2.07-153.44%――35.05%
CELUCELU40Underperform$20.45M-0.35142.25%―-58.14%47.25%
ALGSALGS38Underperform$14.80M-0.33-206.30%―1171.58%49.20%

* Healthcare Sector Average

Performance Comparison

0%100%CUECELUALGSMAIAACRVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CUE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CUECue Biopharma16.12-1.10-6.39%
CELUCelularity Inc.0.63-0.89-58.55%
ALGSAligos Therapeutics, Inc.2.10-4.92-70.09%
MAIAMAIA Biotechnology, Inc.1.000.000.00%
ACRVAcrivon Therapeutics, Inc.1.45-0.93-39.08%

Cue Biopharma Corporate Events

Business Operations and StrategyProduct-Related Announcements

Cue Biopharma reports positive Phase 2 CUE-221 data

Positive
Sep 21, 2026

On September 20, 2026, Cue Biopharma reported positive topline data from a Phase 2 trial of CUE-221 in moderate to severe chronic spontaneous urticaria conducted in China with 145 patients whose disease was inadequately controlled on H1 antihistamine...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 14, 2026